Streetbeat News

Analyst Ratings

COST

Costco Wholesale (NASDAQ:COST) has seen significant bullish activity in its options market, with 41 unusual trades identified. The majority of these trades are call options, indicating a positive sentiment among traders. Analysts have mixed ratings, with price targets ranging from $890 to $975. The stock is currently trading at $894.29, slightly down by 0.25%, and is approaching overbought levels according to RSI indicators.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:15 pm

APO

Recent options trading activity for Apollo Global Management (NYSE:APO) shows a bearish sentiment among major investors, with 50% of trades being bearish. The stock is currently priced at $106.61, down 0.92%, and analysts have set an average price target of $134.0. Despite the bearish options activity, analysts from Argus Research and Deutsche Bank maintain a Buy rating, with price targets of $125 and $124, respectively.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:00 pm

VRDN

Viridian Therapeutics (NASDAQ:VRDN) has received varied analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased slightly to $34.0. Analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance. Despite challenges in revenue growth and profitability, Viridian's debt management is sound.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:00 pm

MOH

Molina Healthcare (NYSE:MOH) has been analyzed by 13 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $368.69, down 3.46% from the previous $381.92. Analysts have adjusted their ratings and price targets in response to market conditions. Molina Healthcare has shown a positive revenue growth rate of 18.65% as of June 2024, but faces challenges with a net margin of 3.05%. The company has a strong ROE of 6.45% and a conservative debt-to-equity ratio of 0.49.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:00 pm

PSA

Public Storage shares remain stable following RBC Capital's initiation of coverage with a Sector Perform rating and a $358 price target.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 7:52 pm

MCD

Recent options activity for McDonald's (NYSE:MCD) shows a bullish sentiment among large investors, with a focus on a price range of $260 to $310. Analysts maintain a positive outlook with price targets ranging from $320 to $360.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 7:01 pm

ACGL

Analysts have provided mixed evaluations of Arch Capital Group (NASDAQ:ACGL) over the past three months, with a positive shift in average price targets. The current average target is $114.42, up 5.32% from the previous $108.64. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. Arch Capital Group has shown strong financial health with impressive revenue growth, net margin, and return on equity.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 7:01 pm

AAPL

GOOG

GOOGL

Apple released the iPhone 16 lineup, sparking mixed reactions and a four-week low in stock prices. The new models feature upgraded chips and AI integration. Competitors like Google's Pixel 9 and Samsung's Galaxy S24 offer alternatives with similar AI features.

Portfolio Pulse from Natan Ponieman

September 10, 2024 | 6:58 pm

HRMY

Harmony Biosciences is seeing strong growth with its drug Wakix, which has increased sales and patient numbers. UBS has initiated coverage with a Buy rating and a $56 price target, citing potential growth in the narcolepsy market and recent strategic acquisitions.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:56 pm

RLAY

Relay Therapeutics (NASDAQ:RLAY) faces a downgrade from Oppenheimer due to concerns over the efficacy of its PI3K inhibitor, RLY-2608, in a competitive market. The clinical benefit rate was 57%, but competitors may offer more selective and effective treatments. RLAY stock fell 6.94% following the news.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:50 pm